Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Cancer Gene Ther. 2012 May 4;19(6):431–442. doi: 10.1038/cgt.2012.21

Figure 6.

Figure 6

Carrier cell adenovirus delivery achieves lower off-site viral titers. Nude mice harboring orthotopic U87 malignant glioma in the right hemisphere were injected, using the same burr-hole, with HB1.F3-CD-GFP cells loaded with CRAd-S-pk7 or the equivalent amount of oncolytic adenovirus (2.5×107 i.u./mouse). In vivo CRAd-S-pk7 replication (n=5 per group per time point) was quantified for each hemisphere separately (right hemisphere/injected vs. left hemispheres/non-injected) via qRT-PCR (a, b) for adenoviral E1A and by adenoviral progeny titer assay (c, d). Error bars represent SEM; ***, P-value <0.001; **, P-value <0.01; *, P-value <0.05; Non significant differences are not depicted.